New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For COV;INTC;MDT;VRTX;BSX;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 16, 2015
07:30 EDTMDTAmerican College of Cardiology to hold an expo
Subscribe for More Information
07:25 EDTBSXBoston Scientific Watchman indication 'very favorable,' says Bernstein
Subscribe for More Information
07:22 EDTMDTMedtronic Edwards Lifesciences data 'impressive,' says Bernstein
Subscribe for More Information
March 15, 2015
15:27 EDTMDTMedtronic unveils data from high risk study of the CoreValve U.S. pivotal trial
Subscribe for More Information
15:23 EDTMDTMedtronic unveils preclinical outcomes of its novel Drug-Filled Stent
Subscribe for More Information
15:20 EDTMDTMedtronic announces outcomes for its next-generation CoreValve Evolut R System
Medtronic announced initial clinical outcomes for its next-generation CoreValve Evolut R System. At 30-days, the new recapturable, self-expanding valve showed no incidents of all-cause mortality or stroke in a high and extreme risk patient population. Data from the Evolut R Study, which enrolled 60 patients from six centers in the United Kingdom, Australia and New Zealand, were unveiled today at the 64th Annual Scientific Session of the American College of Cardiology. The CoreValve Evolut R System is not approved for commercial use in the United States where it is currently undergoing clinical trials. "Initial clinical experience with the Evolut R system is remarkable and ushers in a new era of TAVR technology that provides increased confidence with recapturability, excellent procedural results, and impressive clinical outcomes," said Ian Meredith, M.D., of Monash Heart - Monash Health, Melbourne, Australia, who is one of the investigators of the study. "The 14 French equivalent delivery system allowed transfemoral access for most patients and the recapturable technology enabled implanters to optimize valve placement for improved annular sealing and reduced conduction disturbances without compromise on mortality or stroke."
March 13, 2015
18:57 EDTBSXBoston Scientific receives FDA approval for WATCHMAN device
Subscribe for More Information
17:58 EDTINTCIntel should be bought after recent slide, Barron's says
Subscribe for More Information
14:34 EDTJNJU.S. appeals court revives lawsuit over J&J's Benecol assertions
Subscribe for More Information
11:19 EDTVRTXBioMarin rallies amid positive call on DMD drug timeline, takeover rumor
The shares of drug maker BioMarin (BMRN) are climbing after research firm Jefferies quoted a regulatory expert as saying that the company's drisapersen drug has a good chance of being approved on an accelerated basis by the FDA. Drisapersen is a treatment for Duchenne Muscular Dystrophy, or DMD. WHAT'S NEW: "There is a strong possibility" that the FDA will grant accelerated approval to drisapersen because there is currently no approved drug for the treatment of DMD, Jefferies analyst Eun Yang quoted the expert as saying. The expert is also optimistic about the outlook for accelerated approval because she had a good experience working with BioMarin while she was with the FDA and because BioMarin has a favorable track record with the FDA, according to Yang. There is a 60% chance that drisapersen will be approved by the end of this year and the stock can rise to $155, versus its current level of about $121.50, if that does occur, the analyst stated. Yang's price target on the stock increased to $135 from $125 and the analyst kept a Buy rating on the shares. WHAT'S NOTABLE: Pharmaceutical giant AstraZeneca (AZN) has been rumored to be interested in buying BioMarin for $175 per share in cash, British newspaper Daily Mail reported. , Piper Jaffray analyst Joshua Schimmer wrote in a note to investors this morning that BioMarin, along with Vertex (VRTX) and Incyte (INCY), have a "clear path" to joining the group of companies with market caps of over $10B projected to deliver greater than 20% EPS CAGR, which the analyst identified as a set of criteria that has previously pointed to companies that make good potential takeover targets. PRICE ACTION: In mid-morning trading, BioMarin climbed nearly 4% to $120.
09:50 EDTINTCActive equity options trading on open
Subscribe for More Information
08:47 EDTINTCIntel shares look attractive, says Argus
Subscribe for More Information
08:25 EDTINTCPacific Crest remains constructive on Intel
Subscribe for More Information
08:17 EDTINTCMicrosoft price target lowered to $48 from $58 at Pacific Crest
Subscribe for More Information
07:57 EDTINTCIntel shorts should not be closed, says Bernstein
After Intel issued a negative preannouncement based on unfavorable currency and weak business PC demand, Bernstein expects the company to report lower than expected gross margins. The firm calls the effects of currency fluctuations on demand for the company's products "worrisome," and it trimmed its price target on the name to $28 from $30. It says it would not close shorts on Intel "just yet," and keeps an Underperform rating on the shares.
07:48 EDTINTCIntel preannouncement a buying opportunity, says Jefferies
Jefferies says yesterday's negative preannouncement from Intel presents a "particular" buying opportunity. It believes the tech giant's gross margins will expand in the second half of 2015 and keeps a Buy rating on the name. The firm lowered its price target for shares to $48 from $50.
07:42 EDTINTCIntel upgraded to Buy at Canaccord
As previously reported, Canaccord upgraded Intel to Buy from Hold after its pullback yesterday, citing drastically improved fundamentals, including sustained foundry advantages and strong secular momentum. However, Canaccord lowered its price target to $38 from $40 on Intel shares.
07:27 EDTINTC, INTCIntel upgraded to Underperform from Sell at CLSA
CLSA upgraded Intel to Underperform with a $31 price target to reflect limited downside to shares.
07:23 EDTJNJJohnson & Johnson has a conference call hosted by JPMorgan
Subscribe for More Information
06:23 EDTINTCIntel upgraded to Buy from Hold at Canaccord
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use